ReviewNeural regeneration research2021
Topical delivery of nerve growth factor for treatment of ocular and brain disorders.
Review in Neural regeneration research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 28 citations in OpenAlex.
- The neural stem cell‑NSCLC axis: Molecular drivers, microenvironment crosstalk and emerging therapies (Review).International journal of oncology · 2026Review
- Disease mechanisms and translational barriers guide nanocarrier design for nose to brain delivery in Alzheimer's disease.Discover nano · 2026Review
- Aptamer-Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies.Advanced healthcare materials · 2026Review
- Research progress in animal models of dry eye disease: Types, mechanisms, and application prospects.Animal models and experimental medicine · 2026Review
- Intranasal Drug Delivery Technology in the Treatment of Central Nervous System Diseases: Challenges, Advances, and Future Research Directions.Pharmaceutics · 2025Review
- Enhancing Retinal Resilience: The Neuroprotective Promise of BDNF in Diabetic Retinopathy.Life (Basel, Switzerland) · 2025Review
- In silico pentapeptide design for the inhibition between S100 calcium-binding A9 (S100A9) proteins.Journal of molecular modeling · 2025Article
- Influence of Functional Variations in Genes of Neurotrophins and Neurotransmitter Systems on the Development of Retinopathy of Prematurity.International journal of molecular sciences · 2025Article
- Lumbar disc herniation reabsorption: a review of clinical manifestations, mechanisms, and conservative treatments.Frontiers in medicine · 2025Review
- Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases.Biomedicines · 2024Review
- Cornea-SELEX for aptamers targeting the surface of eyes and liposomal drug delivery.Exploration (Beijing, China) · 2024Article
- Corneal neuropathic pain: a review to inform clinical practice.Eye (London, England) · 2024Review
- Neurotrophins in carotid atherosclerosis and stenting.Annals of medicine · 2023Article
- The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke.Pharmaceutics · 2023Review
- Genetically Engineered Artificial Microvesicles Carrying Nerve Growth Factor Restrains the Progression of Autoimmune Encephalomyelitis in an Experimental Mouse Model.International journal of molecular sciences · 2023Article
- Mechanism of Cone Degeneration in Retinitis Pigmentosa.Cellular and molecular neurobiology · 2023Review
- Intranasal nerve growth factor for prevention and recovery of the outcomes of traumatic brain injury.Neural regeneration research · 2023Review
- Neuroprotective Nanoparticles Targeting the Retina: A Polymeric Platform for Ocular Drug Delivery Applications.Pharmaceutics · 2023Article
- A, B, C's of Trk Receptors and Their Ligands in Ocular Repair.International journal of molecular sciences · 2022Review
- Electroacupuncture treatment improves motor function and neurological outcomes after cerebral ischemia/reperfusion injury.Neural regeneration research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotrophins are a family of proteins that support neuronal proliferation, survival, and differentiation in the central and peripheral nervous systems, and are regulators of neuronal plasticity. Nerve growth factor is one of the best-described neurotrophins and has advanced to clinical trials for treatment of ocular and brain diseases due to its trophic and regenerative properties. Prior trials over the past few decades have produced conflicting results, which have principally been ascribed to adverse effects of systemic nerve growth factor administration, together with poor penetrance of the blood-brain barrier that impairs drug delivery. Contrastingly, recent studies have revealed that topical ocular and intranasal nerve growth factor administration are safe and effective, suggesting that topical nerve growth factor delivery is a potential alternative to both systemic and invasive intracerebral delivery. The therapeutic effects of local nerve growth factor delivery have been extensively investigated for different ophthalmic diseases, including neurotrophic keratitis, glaucoma, retinitis pigmentosa, and dry eye disease. Further, promising pharmacologic effects were reported in an optic glioma model, which indicated that topically administered nerve growth factor diffused far beyond where it was topically applied. These findings support the therapeutic potential of delivering topical nerve growth factor preparations intranasally for acquired and degenerative brain disorders. Preliminary clinical findings in both traumatic and non-traumatic acquired brain injuries are encouraging, especially in pediatric patients, and clinical trials are ongoing. The present review will focus on the therapeutic effects of both ocular and intranasal nerve growth factor delivery for diseases of the brain and eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.